MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.,
Figueroa, Maria E., Skrabanek Lucy, Li Yushan, Jiemjit Anchalee, Fandy Tamer E., Paietta Elisabeth, Fernandez Hugo, Tallman Martin S., Greally John M., Carraway Hetty, et al.
, Blood, 2009 Oct 15, Volume 114, Issue 16, p.3448-58, (2009)
Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.,
Santini, Valeria, Melnick Ari, Maciejewski Jaroslaw P., Duprez Estelle, Nervi Clara, Cocco Lucio, Ford Kevin G., and Mufti Ghulam
, Crit Rev Oncol Hematol, 2013 Nov, Volume 88, Issue 2, p.231-45, (2013)
CD99 is a therapeutic target on disease stem cells in myeloid malignancies.,
Chung, Stephen S., Eng William S., Hu Wenhuo, Khalaj Mona, Garrett-Bakelman Francine E., Tavakkoli Montreh, Levine Ross L., Carroll Martin, Klimek Virginia M., Melnick Ari M., et al.
, Sci Transl Med, 2017 Jan 25, Volume 9, Issue 374, (2017)
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.,
Zhou, Li, Opalinska Joanna, Sohal Davendra, Yu Yiting, Mo Yongkai, Bhagat Tushar, Abdel-Wahab Omar, Fazzari Melissa, Figueroa Maria, Alencar Cristina, et al.
, J Biol Chem, 2011 Jul 15, Volume 286, Issue 28, p.25211-23, (2011)